172 related articles for article (PubMed ID: 29373908)
21. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.
Jenkins EO; Deal AM; Anders CK; Prat A; Perou CM; Carey LA; Muss HB
Oncologist; 2014 Oct; 19(10):1076-83. PubMed ID: 25142841
[TBL] [Abstract][Full Text] [Related]
22. The impact of selected risk factors among breast cancer molecular subtypes: a case-only study.
Pizzato M; Carioli G; Rosso S; Zanetti R; La Vecchia C
Breast Cancer Res Treat; 2020 Nov; 184(1):213-220. PubMed ID: 32851454
[TBL] [Abstract][Full Text] [Related]
23. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Molecular Subtypes of Carcinoma of the Breast in Two Different Age Groups: A Single Institution Experience.
Gupta P; Rai NN; Agarwal L; Namdev S
Cureus; 2018 Jun; 10(6):e2834. PubMed ID: 30131927
[TBL] [Abstract][Full Text] [Related]
25. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
27. Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study.
Agresti R; Meneghini E; Baili P; Minicozzi P; Turco A; Cavallo I; Funaro F; Amash H; Berrino F; Tagliabue E; Sant M
Breast Cancer Res Treat; 2016 May; 157(1):179-89. PubMed ID: 27117160
[TBL] [Abstract][Full Text] [Related]
28. Molecular Profiling of Breast Carcinoma in Almadinah, KSA: Immunophenotyping and Clinicopathological Correlation.
Elkablawy MA; Albasry AM; Hussainy AS; Nouh MM; Alhujaily A
Asian Pac J Cancer Prev; 2015; 16(17):7819-24. PubMed ID: 26625804
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
30. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases.
Elidrissi Errahhali M; Elidrissi Errahhali M; Ouarzane M; El Harroudi T; Afqir S; Bellaoui M
BMC Womens Health; 2017 Jan; 17(1):3. PubMed ID: 28068979
[TBL] [Abstract][Full Text] [Related]
31. The distribution of reproductive risk factors disclosed the heterogeneity of receptor-defined breast cancer subtypes among Tanzanian women.
Rweyemamu LP; Akan G; Adolf IC; Magorosa EP; Mosha IJ; Dharsee N; Namkinga LA; Lyantagaye SL; Nateri AS; Atalar F
BMC Womens Health; 2021 Dec; 21(1):423. PubMed ID: 34930226
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
33. Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer.
Kayahan M; İdiz UO; Gucin Z; Erözgen F; Memmi N; Müslümanoğlu M
J Breast Health; 2014 Oct; 10(4):201-208. PubMed ID: 28331672
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes.
Orrù S; Pascariello E; Sotgiu G; Piras D; Saderi L; Muroni MR; Carru C; Arru C; Mocci C; Pinna G; Barbara R; Cossu-Rocca P; De Miglio MR
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052843
[TBL] [Abstract][Full Text] [Related]
35. Combined
Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
[TBL] [Abstract][Full Text] [Related]
36. Effect of Ki-67 assessment in the distribution of breast cancer subtypes: Evaluation in a cohort of Latin American patients.
Yábar A; Meléndez R; Muñoz S; Deneo H; Freire J; Domínguez V; Carrasco-Navarro RM; Diaz ME; Velarde-López RE
Mol Clin Oncol; 2017 Apr; 6(4):503-509. PubMed ID: 28413656
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
38. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of Breast Cancer Subtypes Among Different Ethnicities and Bangladeshi Women: Demographic, Clinicopathological, and Integrated Cancer Informatics Analysis.
Islam D; Islam MS; Dorin SI; Jesmin
Cancer Inform; 2023; 22():11769351221148584. PubMed ID: 36684416
[TBL] [Abstract][Full Text] [Related]
40. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.
Xue C; Wang X; Peng R; Shi Y; Qin T; Liu D; Teng X; Wang S; Zhang L; Yuan Z
Cancer Sci; 2012 Sep; 103(9):1679-87. PubMed ID: 22625227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
